Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis (ALS)
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- MICABO-ALS (NCT04244630)
- Testing
- Antioxidants
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dallas VA Medical Center
Amyotrophic Lateral Sclerosis
Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients
Amyotrophic lateral sclerosis (ALS), the most common motor neuron disease, is a fatal progressive neurodegenerative disease affecting motor cortex, brainstem and spinal cord leading to motor neuron death.
- Trial name
- NCT03377309
- Testing
- Fycompa
- Where
- Lebanon
- Volunteers
- 6 people
- Sponsor
- American University of Beirut Medical Center
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease Progressive Spinal Muscle Atrophy
Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease
Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease Progressive Spinal Muscle Atrophy, Primary Lateral Sclerosis, Multiple Sclerosis
- Trial name
- NCT06320444
- Testing
- 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)
- Where
- Ireland
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
Spinal Muscular Atrophy
SMN Circular RNAs as Potential New Targets and Biomarkers for SMA
Spinal Muscular Atrophy (SMA) is a life-threatening disease in infancy that is caused by inactivating mutations in the Survival Motor Neuron 1 (SMN1) gene1,2.
- Trial name
- CircSMA (NCT05760209)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid
Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis is a uniformly progressive and fatal neurodegenerative disorder for which there is no known cure. In a novel attempt to widen the search for potential therapeutic agents, a NINDS- led cooperative…
- Conditions
- Amyotrophic Lateral Sclerosis, Cerebrospinal Fluid, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT00718393
- Volunteers
- 1 people
- Sponsor
- Drexel University College of Medicine
Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia
Clinical Procedures to Support Research in ALS
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
- Trial name
- CAPTURE-ALS (NCT03489278)
- Where
- 11 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- University of Miami
ALS, ALS (Amyotrophic Lateral Sclerosis)
Systems Biology of Amyotrophic Lateral Sclerosis (ALS)
The goal of this observational study is to identify molecular features in multiple clinical samples and/or the patient environment that are associated with ALS.
- Trial name
- NCT07007390
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Viome
Amyotrophic Lateral Sclerosis
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease.
- Trial name
- FG-CoALS (NCT06147843)
- Testing
- Blood sample
- Where
- 9 sites in France, Germany
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Limoges
Neurodegenerative Diseases, Alzheimer Disease
Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study
In this retrospective register study, clinically classified individuals with neurodegenerative disease from the years 2010-2021 will be verified from the clinical records from KUH and Oulu University Hospital (OUH).
- Conditions
- Neurodegenerative Diseases, Alzheimer Disease, Frontotemporal Dementia, Lewy Body Disease
- Trial name
- DEGERWD (NCT06209515)
- Where
- Finland
- Volunteers
- 61,292 people
- Sponsor
- Kuopio University Hospital
Amyotrophic Lateral Sclerosis
Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis
To evaluate if transcranial magnetic stimulation can be used as a biomarker in Amyotrophic Lateral sclerosis (ALS).
- Trial name
- NCT03793868
- Testing
- Perampanel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
This is a 48-week, randomised, multi-centre, double-blind, placebo-controlled, parallel group investigation of the efficacy and safety of intravenous (IV) ozanezumab (GSK1223249) compared to placebo in subjects with Amyotrophic…
- Trial name
- NCT01753076
- Testing
- Ozanezumab
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 304 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]
The purpose of this study is to evaluate the safety and effectiveness of creatine treatment in amyotrophic lateral sclerosis (ALS). There is currently no known effective treatment for ALS.
- Trial name
- NCT00005674
- Testing
- Creatine
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Spinal Muscular Atrophy
Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy
The primary objective of this proposal is to determine whether oral VPA is effective in treating SMA in adult patients.
- Trial name
- VALIANTSMA (NCT00481013)
- Testing
- Valproic Acid (VPA)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Utah
SMA - Spinal Muscular Atrophy
An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB058)
An Open Label Individual Patient (OLIP) Study of Nusinersen (BIIB058) in a Participant with Spinal Muscular Atrophy Who Previously Participated in an Investigational Study with Nusinersen
- Trial name
- NCT07846696
- Testing
- Nusinersen Injectable Product
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Amyotrophic Lateral Sclerosis
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01786174
- Testing
- Gilenya
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis
ZYIL1 is expected to show benefit in patients with Amyotrophic Lateral Sclerosis (ALS). The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects…
- Trial name
- NCT05981040
- Testing
- ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
- Where
- 7 sites in India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Amyotrophic Lateral Sclerosis
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.
- Trial name
- ADORE (NCT05178810)
- Testing
- FAB122
- Where
- 38 sites in Belgium, France and 9 more
- Volunteers
- 313 people
- Sponsor
- Ferrer Internacional S.A.
ALS, Amyotrophic Lateral Sclerosis
Intermediate Expanded Access Protocol CNMAu8.EAP04
An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, PALS
- Trial name
- NCT06408727
- Testing
- CNM-Au8
- Where
- 8 sites in United States
- Sponsor
- Clene Nanomedicine
Duchenne Muscular Dystrophy, Spinal Muscular Atrophy
Optimum Insufflation Capacity in NMD
Patients with underlying neuromuscular disorder (NMD) often suffer from weakness in the inspiratory and expiratory muscles. Consequently they do not have the strength to generate the minimum flow of 160 to 300 liters/minute for…
- Conditions
- Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Chronic Respiratory Insufficiency
- Trial name
- NCT01981915
- Testing
- IPPB, LIAM
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Universität Duisburg-Essen
Upper Motor Neuron Disease
Tracking Self-Reported Functional Needs and Quality of Life
The study aims to characterize the population of Cionic Neural Sleeve users and assess their health-related quality of life.
- Trial name
- NCT07284810
- Testing
- Cionic Neural Sleeve System
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Cionic, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.